22179-86-8

Basic information

• Product Name: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME
• Synonyms: BUTTPARK 33\04-34;4-TRIFLUOROMETHYLBENZAMIDE OXIME;4-(TRIFLUOROMETHYL)BENZAMIDOXIME;N-HYDROXY-4-TRIFLUOROMETHYLBENZAMIDINE;N'-HYDROXY-4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE;4-(Trifluoromethyl)benzamidoxime 97%;4-(Trifluoromethyl)benzamidoxime97%;N'-Hydroxy-4-(trifluoromethyl)benzenecarboximidamide, Tech.
• CAS NO: 22179-86-8
• Molecular Formula: C₈H₇F₃N₂O
• Molecular Weight: 204.15
• Product Categories: pharmacetical
• Mol File: 22179-86-8.mol
• Article Data: 58

Chemical Properties

• Melting Point: 125-130 °C(lit.)
• Boiling Point: 297.106 °C at 760 mmHg
• Flash Point: 133.485 °C
• Appearance: /
• Density: 1.401 g/cm³
• Vapor Pressure: 0.000619mmHg at 25°C
• Refractive Index: 1.499
• PKA: 13.71±0.50(Predicted)
• CAS DataBase Reference: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(22179-86-8)
• EPA Substance Registry System: 4-(TRIFLUOROMETHYL)BENZAMIDOXIME(22179-86-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-60-37
• WGK Germany: 3
• Hazardous Substances Data: 22179-86-8(Hazardous Substances Data)

Usage

Description

4-(TRIFLUOROMETHYL)BENZAMIDOXIME, also known as N-Hydroxy-4-(trifluoromethyl)benzamidine, is an organic compound with the molecular formula C8H6F3N2O. It is characterized by the presence of a trifluoromethyl group attached to a benzene ring, with an amidoxime functional group attached to the nitrogen atom. 4-(TRIFLUOROMETHYL)BENZAMIDOXIME is of interest due to its potential applications in the synthesis of various compounds, particularly those with biological activities.

Uses

Used in Pharmaceutical Industry:
4-(TRIFLUOROMETHYL)BENZAMIDOXIME is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of various molecules with potential therapeutic applications.
Used in Anticancer Applications:
In the field of oncology, 4-(TRIFLUOROMETHYL)BENZAMIDOXIME is used as a key intermediate in the synthesis of 5-(3-chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazole, a potential anticancer agent. 4-(TRIFLUOROMETHYL)BENZAMIDOXIME may exhibit inhibitory effects on tumor growth and progression, making it a promising candidate for further research and development in cancer treatment.

InChI:InChI=1/C8H7F3N2O/c9-8(10,11)6-3-1-5(2-4-6)7(12)13-14/h1-4,14H,(H2,12,13)

Upstream product

• 455-18-5 4-CF₃C₆H₄CN 
• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 66046-34-2 4-(trifluoromethyl)benzaldehyde oxime 
• 402-43-7 p-trifluoromethylphenyl bromide 

Downstream Products

• 40067-74-1 3,3'-bis-(4-trifluoromethyl-phenyl)-5,5'-p-phenylene-bis-[1,2,4]oxadiazole 
• 40067-75-2 3,3'-bis-(4-trifluoromethyl-phenyl)-5,5'-m-phenylene-bis-[1,2,4]oxadiazole 
• 131472-28-1 4-trifluoromethylbenzamidine 
• 1019017-01-6 C₁₃H₁₁F₃N₂O₃ 
• 206882-64-6 2-(4-trifluoromethylphenyl)-4-methylpyrimidine 3-oxide 
• 1571023-66-9 1-(3-(4-methylpiperazin-1-yl)benzyl)-5-(3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)pyridin-2(1H)-one 
• 1613435-83-8 2-(4-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-one 
• 1613435-85-0 2-(4-trifluoromethylphenyl)pyrido[3,4-d]pyrimidin-4-one 
• 1651175-57-3 2-(4-trifluoromethylphenyl)pyrido[4,3-d]pyrimidin-4-one 
• 1001467-35-1 C₁₉H₂₂F₃N₃O₃ 
• 38980-96-0 4-(trifluoromethyl)benzimidamide hydrochloride 
• 1206809-03-1 1-(2,3-dichloro-4-((3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)-2-methylenebutan-1-one 
• 1206808-82-3 5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol 

Relevant articles and documents

Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A

Botulinum neurotoxins (BoNTs) are among the most potent biological toxin known to humans, and are classified as Category A bioterrorism agents by the Centers for Disease Control and prevention (CDC). There are seven known BoNT serotypes (A-G) which have b

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis

The alarming increase in multi- and extensively drug-resistant (MDR and XDR) strains of Mycobacterium tuberculosis (MTB) has triggered the scientific community to search for novel, effective, and safer therapeutics. To this end, a series of 3,5-disubstitu